List view / Grid view
8 December 2015 | By Victoria White
The analysis found a 67% reduction in the risk of disease progression or death in patients receiving idelalisib plus bendamustine and rituximab (BR) compared to placebo plus BR...
8 December 2015 | By Victoria White
Debio1143 is an oral, small molecule inhibitor of IAPs with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitiser in ovarian cancer...
8 December 2015 | By
MGB-BP-3 is an antibiotic that is being developed for the potential treatment of Clostridium difficile infections...
8 December 2015 | By Victoria White
New data, presented at AES 2015, show that Eisai's Fycompa (perampanel) treatment reduces primary and secondary generalised tonic clonic seizures and is well tolerated versus placebo...
8 December 2015 | By Victoria White
This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia...
8 December 2015 | By Victoria White
Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
7 December 2015 | By Victoria White
The data shows that a good proportion of people with partial-onset seizures, who have not responded when treated with carbamazepine, may respond to eslicarbazepine acetate...
7 December 2015 | By Victoria White
Takeda presented long-term data from a Phase II and Phase III trial of Adcetris (brentuximab vedotin) at the 57th American Society of Hematology (ASH) annual meeting...
7 December 2015 | By Victoria White
The follow-up data demonstrated that Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone had an improvement in progression-free survival in patients with relapsed or refractory multiple myeloma...
7 December 2015 | By Victoria White
By mining the DNA of patients with chronic lymphocytic leukaemia (CLL), researchers at Penn Medicine have uncovered 12 mutations that may be targetable using therapies already available for other cancers...
7 December 2015 | By Victoria White
Merck KGaA will also not be pursuing the treatment in pancreatic adenocarcinoma after the drug failed in two late-stage clinical trials...
7 December 2015 | By Cherwell Laboratories
Cherwell Laboratories, specialists in cleanroom microbiology solutions for the pharmaceutical and related industries, has once again supported Pharmig’s Annual Conference...
7 December 2015 | By Victoria White
Breakpoints of new agents are absolutely vital in standardising a global definition of resistance and the point at which increased dosages are needed...
7 December 2015 | By Victoria White
Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.
7 December 2015 | By Victoria White
The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone...
